School of Medicine
Showing 1-10 of 117 Results
-
David Maahs
Lucile Salter Packard Professor of Pediatrics and Professor, by courtesy, of Epidemiology and Population Health
BioDr David M. Maahs is the Lucile Salter Packard Professor of Pediatrics, Division Chief of Pediatric Endocrinology, and Associate Chair for Academic Affairs in Pediatrics at Stanford University and the Lucile Packard Children’s Hospital. He earned his MD followed by Pediatric Residency at the University of New Mexico. After 3 years on New Mexico’s faculty, Dr. Maahs completed a Pediatric Endocrinology fellowship and a concurrent PhD in Epidemiology at the University of Colorado. He remained on Colorado’s faculty for 10 years, advancing to Professor of Pediatrics before moving to Stanford. Prior to his medical career, Dr. Maahs received a BA and MA in English from the University of Kansas and was inspired to pursue a medical career after serving in the Peace Corps with assignments in Tunisia and the Central African Republic.
Dr. Maahs’ leadership experiences include being a past co-Chair (2013-16) for Protocols and Publications with the Type 1 Diabetes Exchange for which he continues as Director of International Collaborations. This complements his role as President-elect for the International Society of Pediatric and Adolescent Diabetes (ISPAD, 2021-25) and Editor-in-Chief for the 2018 ISPAD Clinical Practice Consensus Guidelines. He served on the Professional Practice Committee for the American Diabetes Association (ADA, 2016-18), which writes the annual ADA Standards of Care. Previously, he served on the ADA Scientific Sessions committee representing the Council on Youth. He has also served on national committees for the American Heart Association, the Pediatric Endocrine Society, and multiple journal editorial boards and review committees.
His scholarly interest is improving care and preventing complications in people with type 1 diabetes (T1D). Along with Dr Peter Chase, he is author of the 12th and 13th editions of Understanding Diabetes, or ‘Pink Panther,’ which are the most widely used educational books for children newly diagnosed with T1D, distributed internationally by the Juvenile Diabetes Research Fund (JDRF). More specifically, he has conducted epidemiologic studies that help generate hypotheses for clinical studies, including trials to develop artificial pancreas systems to improve glucose control, lower disease burden, prevent the complications of diabetes, and reduce disparities in diabetes care. He is author or co-author of over 350 research publications. His multi-disciplinary research has been funded by the JDRF, the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK), the Helmsley Charitable Trust, and the National Science Foundation (NSF).
Dr Maahs is Associate Director for the recently formed and NIDDK P30 funded Stanford University Diabetes Research Center (https://sdrc.stanford.edu). His collaborations extend to his role as Principal Investigator (PI) or steering committee member for NIH funded multi-center clinical trials including the FLEX, PERL, and ACTION studies as well as multiple Artificial Pancreas clinical trials. Education, mentorship, and training leadership includes being Program Director with Dr. Georgeanna Klingensmith on the Barbara Davis Center T32 and K12 training grants in Pediatric Endocrinology while at the University of Colorado. He is the PI on the Stanford NIH funded K12 "Training Research Leaders in Type 1 Diabetes.' Dr Maahs is also the Associate Chair for Academic Affairs for the Department of Pediatrics.
While in the Peace Corps, David met his wife, Christine Walravens, who is also a Pediatrician at Stanford. They enjoy outdoor activities and traveling with their adult children. -
Crystal Mackall
Ernest and Amelia Gallo Family Professor and Professor of Pediatrics and of Medicine
Current Research and Scholarly InterestsRecent clinical studies, by us and others, have demonstrated that genetically engineered T cells can eradicate cancers resistant to all other therapies. We are identifying new targets for these therapeutics, exploring pathways of resistance to current cell therapies and creating next generation platforms to overcome therapeutic resistance. We have discovered novel insights into the biology of human T cell exhaustion and developed approaches to prevent and reverse this phenomenon.
